|
|
|
|
|||||
|
|
|
Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a ‘Neutral’ rating on the stock and increased its price target to $62 from $61.
The price hike comes as UBS expects higher sales for Incyte’s Niktimvo, a treatment for chronic Graft-versus-Host Disease (cGVHD). Amid the expected higher sales, UBS has revised its 2026 earnings per share estimate of $6.36 from $6.26.
UBS also maintained a 9.5x price-to-earnings multiple on Incyte, as it expects the company’s second-quarter earnings call to provide clarity on the company’s strategic direction. The company’s pipeline has already received a boost following the FDA’s extension of the review for ruxolitinib cream for pediatric atopic dermatitis.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in oncology and inflammation & autoimmunity. It also boasts a growing portfolio of treatments for other diseases, including those in dermatology.
While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks.
Disclosure: None. This article is originally published at Insider Monkey.
| Jul-24 | |
| Jul-24 | |
| Jul-24 | |
| Jul-24 | |
| Jul-23 | |
| Jul-22 | |
| Jul-17 | |
| Jul-16 | |
| Jul-10 | |
| Jul-10 | |
| Jul-09 | |
| Jul-02 | |
| Jul-01 | |
| Jun-30 | |
| Jun-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite